INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Medline Industries, Inc. - MDLN

Pomerantz LLP is investigating claims on behalf of investors of Medline Industries, Inc. (“Medline” or the “Company”) (NASDAQ: MDLN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Medline and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On June 2, 2026, the U.S. Food and Drug Administration published a warning letter addressed to Medline regarding “significant violations of Current Good Manufacturing Practice regulations for finished pharmaceuticals,” stating, among other things, that Medline “failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications.” On this news, Medline’s stock price fell $2.56 per share, or 7.16%, to close at $33.19 per share on June 2, 2026.